Get the Stockscreener App
0.3801
2.15%
0.008
Adial Pharmaceuticals Inc stock is traded at $0.3801, with a volume of 632.30K.
It is up +2.15% in the last 24 hours and down -19.21% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$0.3721
Open:
$0.365
24h Volume:
632.30K
Relative Volume:
0.08
Market Cap:
$8.30M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.0658
EPS:
-5.78
Net Cash Flow:
$-7.34M
1W Performance:
-3.53%
1M Performance:
-19.21%
6M Performance:
-51.64%
1Y Performance:
-62.36%
1-Day Range:
$0.363
$0.392
1-Week Range:
$0.3609
$0.4049
52-Week Range:
$0.22
$1.30
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.3801 | 8.22M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals files to register resale of 6.7M shares from warrant conversions - MSN
U.S. Senate backs expanded endpoints for alcohol use disorder trials - Investing.com
Adial Pharmaceuticals Encouraged By U.S. Senate Support for - GlobeNewswire
Senate Committee Votes 26-3 to Support Expanded Drug Trial Metrics: Adial's AUD Treatment Strategy Validated - Stock Titan
Price Channel Expanding on Adial Pharmaceuticals Inc.’s ChartJuly 2025 Outlook & Consistent Growth Stock Picks - beatles.ru
Is Adial Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Trade Ideas & Community Trade Idea Sharing - thegnnews.com
What moving averages say about Adial Pharmaceuticals Inc.July 2025 Catalysts & Free High Accuracy Swing Entry Alerts - Newser
Analyzing Adial Pharmaceuticals Inc. with multi timeframe chartsEarnings Miss & Advanced Technical Signal Analysis - Newser
Is Adial Pharmaceuticals Inc. stock entering bullish territoryJobs Report & Momentum Based Trading Signals - Newser
Backtesting results for Adial Pharmaceuticals Inc. trading strategiesBear Alert & Risk Adjusted Buy/Sell Alerts - Newser
Multi asset correlation models including Adial Pharmaceuticals Inc.July 2025 Levels & Low Risk High Reward Trade Ideas - Newser
Adial Pharmaceuticals Receives Hold Rating from Maxim Group - AInvest
Key metrics from Adial Pharmaceuticals Inc.’s quarterly data2025 Stock Rankings & Daily Entry Point Trade Alerts - Newser
Can Adial Pharmaceuticals Inc. Bounce Back From Weekly Low2025 Performance Recap & Weekly Chart Analysis and Trade Guides - 선데이타임즈
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Expands By 919.9% - Defense World
Exit strategy if you’re trapped in Adial Pharmaceuticals Inc.Market Trend Summary & Reliable Momentum Entry Alerts - Newser
Adial Pharmaceuticals Q2 Earnings: Net Loss Down to $2M - AInvest
Adial Pharmaceuticals expects cash to fund operations into Q2 of 2026 - TipRanks
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - TradingView
Adial's Genetic-Targeted Alcohol Treatment Heads to Phase 3 After FDA Green Light - Stock Titan
Will Adial Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsMarket Activity Report & Low Risk Entry Point Guides - Newser
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Will Adial Pharmaceuticals Inc. outperform the marketFree Community Shared Smart Money Signals - Newser
Why Adial Pharmaceuticals Inc. stock attracts strong analyst attentionStock Holding Strategy Long-Term Summary Sheet - Newser
ADIL financial health comparison - AInvest
Price momentum metrics for Adial Pharmaceuticals Inc. explainedFree Weekly Chart Analysis With Entry Advice - Newser
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Adial Pharmaceuticals Completes FDA Meeting, Advances AD04 into Phase 3 Clinical Development - AInvest
Adial Pharmaceuticals' Regulatory and Strategic Momentum with AD04: A Catalyst for Partnership and Growth in a High-Potential Market - AInvest
Adial Pharmaceuticals completes FDA meeting for alcohol disorder drug By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting | AD - GuruFocus
Adial Pharmaceuticals completes FDA meeting for alcohol disorder drug - Investing.com
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting - GlobeNewswire
Adial Pharmaceuticals Completes Successful FDA Meeting for Phase 3 Trial of AD04 for Alcohol Use Disorder Treatment. - AInvest
Adial's Alcohol Addiction Treatment Gets FDA Green Light for Pivotal Phase 3 Trial, Partnership Talks Heat Up - Stock Titan
Candlestick Reversal Detected on Adial Pharmaceuticals Inc.’s ChartProfit Focused Trade Alerts - beatles.ru
Sentiment Tools Show Shift in Trader Mood on Adial Pharmaceuticals Inc.Weekly Stock Opportunity Radar Scanner Activated - beatles.ru
Technical Bounce Expected in Adial Pharmaceuticals Inc. Next WeekSector Based Breakout Stock Forecast Issued - metal.it
Published on: 2025-08-04 18:30:20 - beatles.ru
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
What is the risk reward ratio of investing in Adial Pharmaceuticals Inc. stockBuild wealth with reliable stock picks - Jammu Links News
How many analysts rate Adial Pharmaceuticals Inc. as a “Buy”Rapid growth opportunities - Jammu Links News
What drives Adial Pharmaceuticals Inc. stock priceTriple returns potential - Jammu Links News
How does Adial Pharmaceuticals Inc. generate profit in a changing economyBoost your returns with professional guidance - Jammu Links News
What analysts say about Adial Pharmaceuticals Inc. stockHigh-profit capital plays - Jammu Links News
How strong is Adial Pharmaceuticals Inc. company’s balance sheetFree Stock Selection - Jammu Links News
Adial Pharmaceuticals Approves Share Increase Amid Ongoing Financial Struggles - AInvest
What is Adial Pharmaceuticals Inc. company’s growth strategyGet timely alerts on market opportunities - Jammu Links News
What is the dividend policy of Adial Pharmaceuticals Inc. stockGet exclusive market analysis for investors - Jammu Links News
What are Adial Pharmaceuticals Inc. company’s key revenue driversMaximize returns with disciplined trading approaches - Jammu Links News
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):